|Healthcare Review: Aratana Therapeutics, BSD Medical, Xencor, CombiMatrix, Acadia Pharmaceuticals|
|By Staff and Wire Reports|
|Tuesday, 15 July 2014 13:56|
Aratana Therapeutics ($PETX) files an S-3 for a $100M mixed shelf offering plus the registration of 500,000 shares of common stock for sale by Avalon Ventures.
BSD Medical ($BSDM) initiates a 28-patient Phase 1/2 clinical trial evaluating the use of hyperthermia combined with proton radiotherapy as a treatment for patients with unresectable soft tissue sarcoma. Investigators will use the company's BSD-2000 System or BSD-500 System to deliver the hyperthermia. The systems deliver localized therapeutic heating by applying radiofrequency (RF) energy.
Xencor ($XNCR) promotes VP of Research John R. Desjarlais, Ph.D., to SVP of Research and Chief Scientific Officer. He joined the company in 2001 and was promoted to VP of Research in 2006.
The New York Department of Public Health grants conditional approval for CombiMatrix's (NASDAQ:CBMX) chromosomal microarray CombiSNP Array for Pediatric Analysis for testing patient samples. The American College of Medical Genetics recommends the test for pediatric development disorders to determine if genetic defects are a factor. Under conditional approval, the company will be able to market the test in NY while the test is under Clinical Laboratory Reference System review. Upon the completion of the review, the test will receive full marketing approval (if additional information is not required).
Acadia Pharmaceuticals (NASDAQ:ACAD) hires Stephen Davis as EVP, CFO and Chief Business Officer reporting to CEO Uli Hacksell, Ph.D. Mr. Davis joins the company from Heron Therapeutics where he was EVP and COO.